Roles of the immune system in cancer: from tumor initiation to metastatic progression

Genes & Development, Journal Year: 2018, Volume and Issue: 32(19-20), P. 1267 - 1284

Published: Oct. 1, 2018

The presence of inflammatory immune cells in human tumors raises a fundamental question oncology: How do cancer avoid the destruction by attack? In principle, tumor development can be controlled cytotoxic innate and adaptive cells; however, as develops from neoplastic tissue to clinically detectable tumors, evolve different mechanisms that mimic peripheral tolerance order tumoricidal attack. Here, we provide an update recent accomplishments, unifying concepts, future challenges study tumor-associated cells, with emphasis on metastatic carcinomas.

Language: Английский

---

Emerging concepts in the science of vaccine adjuvants

Nature Reviews Drug Discovery, Journal Year: 2021, Volume and Issue: 20(6), P. 454 - 475

Published: April 6, 2021

Language: Английский

---

Cellular Senescence: Aging, Cancer, and Injury

Physiological Reviews, Journal Year: 2019, Volume and Issue: 99(2), P. 1047 - 1078

Published: Jan. 16, 2019

Cellular senescence is a permanent state of cell cycle arrest that occurs in proliferating cells subjected to different stresses. Senescence is, therefore, cellular defense mechanism prevents the acquire an unnecessary damage. The senescent accompanied by failure re-enter response mitogenic stimuli, enhanced secretory phenotype and resistance death. takes place several tissues during physiological pathological processes such as tissue remodeling, injury, cancer, aging. Although one causative aging it responsible aging-related disorders, can also play positive role. In embryogenesis are required for proper development embryo repair. works potent barrier prevent tumorigenesis. Therefore, identification characterization key features senescence, induction cancer cells, or elimination pharmacological interventions gaining consideration fields research. Here, we describe known cell-autonomous, noncell-autonomous regulators attempt discuss functional role this fundamental process contexts light novel therapeutic targets.

Language: Английский

---

Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity

Immunity, Journal Year: 2019, Volume and Issue: 50(4), P. 778 - 795

Published: April 1, 2019

Language: Английский

---

Control of Metastasis by NK Cells

Cancer Cell, Journal Year: 2017, Volume and Issue: 32(2), P. 135 - 154

Published: Aug. 1, 2017

Language: Английский

---

Natural killer cells in cancer biology and therapy

Molecular Cancer, Journal Year: 2020, Volume and Issue: 19(1)

Published: Aug. 6, 2020

Abstract The tumor microenvironment is highly complex, and immune escape currently considered an important hallmark of cancer, largely contributing to progression metastasis. Named for their capability killing target cells autonomously, natural killer (NK) serve as the main effector toward cancer in innate immunity are heterogeneous microenvironment. Most current treatment options harnessing focus on T cell-immunity, either by promoting activating signals or suppressing inhibitory ones. limited success achieved cell immunotherapy highlights importance developing new-generation immunotherapeutics, example utilizing previously ignored NK cells. Although tumors also evolve resist cell-induced cytotoxicity, cytokine supplement, blockade suppressive molecules genetic engineering may overcome such resistance with great promise both solid hematological malignancies. In this review, we summarized fundamental characteristics recent advances within immunometabolic microenvironment, discussed potential application limitations emerging cell-based therapeutic strategies era presicion medicine.

Language: Английский

---

NK cell-based cancer immunotherapy: from basic biology to clinical development

Journal of Hematology & Oncology, Journal Year: 2021, Volume and Issue: 14(1)

Published: Jan. 6, 2021

Abstract Natural killer (NK) cell is a specialized immune effector type that plays critical role in activation against abnormal cells. Different from events required for T activation, NK governed by the interaction of receptors with target cells, independent antigen processing and presentation. Due to relatively unsophisticated cues has gained significant attention field cancer immunotherapy. Many efforts are emerging developing engineering cell-based In this review, we provide our current understandings biology, ongoing pre-clinical clinical development therapies discuss progress, challenges, future perspectives.

Language: Английский

---

Immunometabolism and natural killer cell responses

Nature reviews. Immunology, Journal Year: 2019, Volume and Issue: 19(5), P. 282 - 290

Published: Feb. 26, 2019

Language: Английский

---

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

Frontiers in Oncology, Journal Year: 2018, Volume and Issue: 8

Published: June 4, 2018

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic approved for oncology patients and top-selling drug nearly decade sales reaching $8.58 billion in 2016. Since its initial approval 1997, it has improved outcomes all B-cell malignancies, including diffuse large lymphoma, follicular chronic lymphocytic leukemia. Despite widespread use, most mechanistic data have been gathered from vitro studies while roles of various response mechanisms humans are still largely undetermined. Polymorphisms Fc gamma receptor complement protein genes implicated as potential predictors differential rituximab, but not yet shown sufficient influence impact clinical decisions. Unlike targeted therapies developed today, no known biomarkers indicate target engagement/tumor identified, aside reduced tumor burden. The lack companion beyond CD20 itself made difficult predict which will respond any given anti-CD20 antibody. In past decade, two new antibodies approved: ofatumumab, binds distinct epitope CD20, obinutuzumab, mAb derived rituximab modifications portion glycosylation. Both fully humanized biological activity that rituximab. addition these antibodies, another imminent change lymphoma treatment multitude biosimilars becoming available rituximab's patent expires. While use likely continue, increase global access therapy. This review discusses current research into response, well newer therapies. Increased ability assess effectiveness an individual patient, along availability alternative lead dramatic changes how we going forward.

Language: Английский

---

Srebp-controlled glucose metabolism is essential for NK cell functional responses

Nature Immunology, Journal Year: 2017, Volume and Issue: 18(11), P. 1197 - 1206

Published: Sept. 18, 2017

Language: Английский

---